Sourcing · Regulatory

Pharmaceutical compounding rules, summarised from primary sources

Sourcing › Regulatory MHRA EMA research use only

Closed

b.jansenTL226 Feb 2025#1

Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable.

Asking what a regulator's document actually says, since the summaries of it disagree.

I have the primary document open and two secondhand accounts of it that cannot both be right. The primary document is narrower than either.

My question is whether I am reading the scope of it correctly, and what the correct reading rules out as well as what it permits.

0 likes 17mo

ma.balogunTL226 Feb 2025#2

The arithmetic in the opening post is right; the assumption feeding it is the part to check.

On pharmaceutical compounding rules I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

0 likes 17mo

e.dalgleishTL3Regular26 Feb 2025#3

ma.balogun, post #2: The arithmetic in the opening post is right; the assumption feeding it is the part to check. On pharmaceutical compounding rules I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated. Go to post

Useful. I have added it to my own notes with the date on it.

0 likes in reply to #2 17mo

r.ilungaTL227 Feb 2025#4

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

21 likes in reply to #2 17mo

integrator_logTL3Regular27 Feb 2025#5

Everything in post #4 holds. The case it does not cover is the one I have.

Since pharmaceutical compounding rules keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

9 likes 17mo

f.lindholmTL227 Feb 2025#6

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

A qualification I should have led with rather than closed on.

2 likes 17mo

buffer_sheetTL3Regular27 Feb 2025#7

r.ilunga, post #4: An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. Go to post

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

0 likes in reply to #4 17mo

b.wikstromTL227 Feb 2025 · edited#8

One more thing on pharmaceutical compounding rules that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.

28 likes 17mo

integrator_draftTL3Regular27 Feb 2025#9

Contradicting a claim in this subcategory is most useful when it comes with a link to the primary source and a date of access.

14 likes 17mo

n.szaboTL227 Feb 2025#10

b.wikstrom, post #8: One more thing on pharmaceutical compounding rules that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears. Go to post

Seconded. It reads as careful rather than confident, which is the right register.

5 likes in reply to #8 17mo

r.marsdenTL3Regular27 Feb 2025#11

I would put moderate confidence on the mainstream reading of pharmaceutical compounding rules and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

28 likes 17mo

a.amankwahTL227 Feb 2025#12

Worth separating two things that post #11 runs together.

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

That is the honest state of it as of this week.

0 likes 17mo

figure_reviewTL2Member27 Feb 2025#13

a.amankwah, post #12: Worth separating two things that post #11 runs together. Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. That is the honest state of it as of this week. Go to post

Post #12 answers the question as asked. The question underneath it is different.

Small correction to my own earlier position on pharmaceutical compounding rules. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.

2 likes in reply to #12 17mo

j.marchettiTL227 Feb 2025#14

e.dalgleish, post #3: Useful. I have added it to my own notes with the date on it. Go to post

The question underneath pharmaceutical compounding rules is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

9 likes in reply to #3 17mo

k.farrugiaTL3Regular27 Feb 2025#15

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

0 likes 17mo

r.oyelaranTL227 Feb 2025#16

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

I would put the burden of proof on the interesting explanation, not the dull one.

0 likes 17mo

lyophil_marginTL3Regular27 Feb 2025#17

j.marchetti, post #14: The question underneath pharmaceutical compounding rules is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help. Go to post

Post #16 is right about the mechanism and I think understates the practical bit.

Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.

Marking that as an opinion rather than a finding.

5 likes in reply to #14 17mo

m.yildizTL228 Feb 2025 · edited#18

Coming back to post #14, because the follow-up matters more than the original answer.

Nobody has said the unglamorous part of pharmaceutical compounding rules yet, so: most of the variation is explained by things that are boring to write about and easy to check.

14 likes 17mo

e.mikkelsenTL2Member28 Feb 2025#19

r.ilunga, post #4: An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. Go to post

The reason pharmaceutical compounding rules keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.

0 likes in reply to #4 17mo

e.tammTL228 Feb 2025#20

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

2 likes 17mo

h.koodziejTL2Member28 Feb 2025#21

Where I part company with post #19, and it is a narrow parting.

Filing a mild objection to the consensus on pharmaceutical compounding rules. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.

0 likes 17mo

e.mwangiTL228 Feb 2025#22

A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.

22 likes 17mo

trough_indexTL3Regular28 Feb 2025#23

figure_review, post #13: Post #12 answers the question as asked. The question underneath it is different. Small correction to my own earlier position on pharmaceutical compounding rules. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely. Go to post

This is the first time the answer has come with its own limits attached. Appreciated.

6 likes in reply to #13 17mo

h.fonsecaTL228 Feb 2025#24

Adding the measurement that post #22 says would settle it.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

I keep a log of this specifically because memory is unreliable about it.

1 like 17mo

n.bridgewaterTL2Member28 Feb 2025#25

Post #24 put the caveat in the right place and I want to underline it.

Import rules for personal quantities differ from commercial import rules and both differ by country. Establishing your own position is not something a forum can do for you.

The right answer here may simply be that it has not been measured.

30 likes 17mo

ne.laurentTL228 Feb 2025#26

m.yildiz, post #18: Coming back to post #14, because the follow-up matters more than the original answer. Nobody has said the unglamorous part of pharmaceutical compounding rules yet, so: most of the variation is explained by things that are boring to write about and easy to check. Go to post

Building on post #24 rather than restating it.

Two sentences on pharmaceutical compounding rules and then I will stop, because the rest is speculation and the thread is better without mine.

What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.

15 likes in reply to #18 17mo

v.milanoviTL3Regular28 Feb 2025#27

The reason pharmaceutical compounding rules is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.

3 likes in reply to #13 17mo

s.lundgrenTL228 Feb 2025#28

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

The short answer was in the first line; everything after is the working.

0 likes 17mo

ambient_draftTL3Regular28 Feb 2025#29

An observation about pharmaceutical compounding rules that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.

0 likes 17mo

n.chowdhuryTL228 Feb 2025#30

b.jansen, post #1: Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have the primary document open and two secondhand accounts of it that cannot both be right. The primary document… Go to post

Post #27 is right about the mechanism and I think understates the practical bit.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

Anyone with a larger sample, please post it.

0 likes in reply to #1 17mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →